A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).

Trial Profile

A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs IMM 529 (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions; First in man
  • Sponsors Immuron
  • Most Recent Events

    • 09 Aug 2017 According to an Immuron media release, this trial is scheduled to be initiated within the next few weeks (September 2017). Top line results from the trial expected in Q4 2018
    • 09 Aug 2017 According to an Immuron media release, this trial has been approved by the Hadassah Medical Center Ethics Committee and the Israeli Ministry of Health's (MoH) office.
    • 14 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top